US FDA Flags Overdosing of Novo Nordisk's Semaglutide in Patients

MT Newswires Live07-27

The US Food and Drug Administration on Friday warned patients and healthcare providers of possible dosing errors related to Novo Nordisk's (NVO) weight loss drug semaglutide.

The agency said it had received reports of adverse events, some requiring hospitalization, caused by patients measuring and self-administering incorrect doses of the drug and healthcare providers miscalculating doses of the medicine.

The FDA said there was "unfamiliarity" and "confusion" on how to withdraw and measure the medication from a vial. It also said that many of the patients using semaglutide "lacked experience" with self-injections which may have resulted in overdosage.

Overdosage of semaglutide can result in severe nausea, severe vomiting, and low blood sugar levels, according to the drug's prescribing information.

Novo Nordisk did not immediately respond to a request for comment from MT Newswires.

Price: 127.05, Change: -0.81, Percent Change: -0.63

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2454741533?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-27 03:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2454741533","market":"sg","top_or_hot":-1,"title":"US FDA Flags Overdosing of Novo Nordisk's Semaglutide in Patients","media":"MT Newswires Live","content":"<html><body><p> The US Food and Drug Administration on Friday warned patients and healthcare providers of possible dosing errors related to Novo Nordisk's (NVO) weight loss drug semaglutide.</p><p>The agency said it had received reports of adverse events, some requiring hospitalization, caused by patients measuring and self-administering incorrect doses of the drug and healthcare providers miscalculating doses of the medicine.</p><p>The FDA said there was \"unfamiliarity\" and \"confusion\" on how to withdraw and measure the medication from a vial. It also said that many of the patients using semaglutide \"lacked experience\" with self-injections which may have resulted in overdosage.</p><p>Overdosage of semaglutide can result in severe nausea, severe vomiting, and low blood sugar levels, according to the drug's prescribing information.</p><p>Novo Nordisk did not immediately respond to a request for comment from MT Newswires.</p><p>Price: 127.05, Change: -0.81, Percent Change: -0.63</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US FDA Flags Overdosing of Novo Nordisk's Semaglutide in Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS FDA Flags Overdosing of Novo Nordisk's Semaglutide in Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-27 03:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The US Food and Drug Administration on Friday warned patients and healthcare providers of possible dosing errors related to Novo Nordisk's (NVO) weight loss drug semaglutide.The agency said it had ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2454741533","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2454741533","pubTimestamp":1722020995,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"The US Food and Drug Administration on Friday warned patients and healthcare providers of possible dosing errors related to Novo Nordisk's (NVO) weight loss drug semaglutide.The agency said it had rec","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4007":"制药","NVO":"诺和诺德","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4532":"文艺复兴科技持仓","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK7104":"黄金","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4585":"ETF&股票定投概念","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)"},"translate_title":"美国FDA警告患者过量服用诺和诺德的索马鲁肽","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"The US Food and Drug Administration on Friday warned patients and healthcare providers of possible dosing errors related to Novo Nordisk's (NVO) weight loss drug semaglutide.The agency said it had received reports of adverse events, some requiring hospitalization, caused by patients measuring and self-administering incorrect doses of the drug and healthcare providers miscalculating doses of the medicine.The FDA said there was \"unfamiliarity\" and \"confusion\" on how to withdraw and measure the medication from a vial. It also said that many of the patients using semaglutide \"lacked experience\" with self-injections which may have resulted in overdosage.Overdosage of semaglutide can result in severe nausea, severe vomiting, and low blood sugar levels, according to the drug's prescribing information.Novo Nordisk did not immediately respond to a request for comment from MT Newswires.Price: 127.05, Change: -0.81, Percent Change: -0.63","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"Policy And Regulatory","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.26.3","shortVersion":"4.26.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2454741533"}